Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Vehicle-Controlled, Multicenter, Double-Masked, Parallel, Phase 2 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of Lotilaner Ophthalmic Gel in Participants With Ocular Rosacea (KORE)

NCT07443202 is registered in ClinicalTrials.gov with Tarsus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07443202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07443202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Vehicle-Controlled, Multicenter, Double-Masked, Parallel, Phase 2 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of Lotilaner Ophthalmic Gel in Participants With Ocular Rosacea (KORE)
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
December 5, 2025
Completion date
December 31, 2027
Enrollment
155 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ocular rosacea